ATE51026T1 - Hybridzellen, die ein hepatitis-b-virus-antigen produzieren, aus hepatocyten und errichteten affenzellen, verfahren zur herstellung dieser hybridzellen und verwendung derselben zur herstellung der obenerwaehnten antigens. - Google Patents

Hybridzellen, die ein hepatitis-b-virus-antigen produzieren, aus hepatocyten und errichteten affenzellen, verfahren zur herstellung dieser hybridzellen und verwendung derselben zur herstellung der obenerwaehnten antigens.

Info

Publication number
ATE51026T1
ATE51026T1 AT86400945T AT86400945T ATE51026T1 AT E51026 T1 ATE51026 T1 AT E51026T1 AT 86400945 T AT86400945 T AT 86400945T AT 86400945 T AT86400945 T AT 86400945T AT E51026 T1 ATE51026 T1 AT E51026T1
Authority
AT
Austria
Prior art keywords
cells
production
hybrid cells
hepatitis
hybrid
Prior art date
Application number
AT86400945T
Other languages
English (en)
Inventor
Nicole Chenciner
Jean-Francois Houssais
Aufargis
Original Assignee
Pasteur Institut
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Centre Nat Rech Scient filed Critical Pasteur Institut
Application granted granted Critical
Publication of ATE51026T1 publication Critical patent/ATE51026T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
AT86400945T 1985-05-02 1986-04-29 Hybridzellen, die ein hepatitis-b-virus-antigen produzieren, aus hepatocyten und errichteten affenzellen, verfahren zur herstellung dieser hybridzellen und verwendung derselben zur herstellung der obenerwaehnten antigens. ATE51026T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR858506706A FR2581393B2 (fr) 1985-05-02 1985-05-02 Cellules hybrides productrices d'un antigene caracteristique du virus de l'hepatite b obtenu a partir d'hepatocytes et de cellules etablies de singe, procede pour l'obtention de ces cellules hybrides et application de celles-ci a la production de l'antigene susdit
EP86400945A EP0200653B1 (de) 1985-05-02 1986-04-29 Hybridzellen, die ein Hepatitis-B-Virus-Antigen produzieren, aus Hepatocyten und errichteten Affenzellen, Verfahren zur Herstellung dieser Hybridzellen und Verwendung derselben zur Herstellung der obenerwähnten Antigens

Publications (1)

Publication Number Publication Date
ATE51026T1 true ATE51026T1 (de) 1990-03-15

Family

ID=9318906

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86400945T ATE51026T1 (de) 1985-05-02 1986-04-29 Hybridzellen, die ein hepatitis-b-virus-antigen produzieren, aus hepatocyten und errichteten affenzellen, verfahren zur herstellung dieser hybridzellen und verwendung derselben zur herstellung der obenerwaehnten antigens.

Country Status (12)

Country Link
US (1) US5112748A (de)
EP (1) EP0200653B1 (de)
JP (1) JPS6229971A (de)
AT (1) ATE51026T1 (de)
CA (1) CA1277934C (de)
DE (1) DE3669529D1 (de)
DK (1) DK204586A (de)
ES (1) ES8703519A1 (de)
FR (1) FR2581393B2 (de)
GR (1) GR861142B (de)
PT (1) PT82505B (de)
WO (1) WO1993013203A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7766329B1 (en) 1992-10-02 2010-08-03 Sierra Design Group Wheel indicator and ticket dispenser apparatus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757169A1 (de) * 1977-12-22 1979-07-05 Hoechst Ag Verfahren zur gewinnung insulin produzierender tierischer zellen
FR2458584A1 (fr) * 1979-06-08 1981-01-02 Pasteur Institut Vecteurs pour le transfert et l'expression de materiel genetique dans une cellule eucaryote et procede pour la production d'une proteine determinee dans des cellules eucaryotes
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
JPS6045848B2 (ja) * 1980-07-31 1985-10-12 株式会社林原生物化学研究所 ヒト成長ホルモンの製造方法
FR2500847B1 (fr) * 1981-03-02 1985-09-13 Pasteur Institut Marqueurs genetiques selectifs pour cellules eucaryotes, procede de mise en oeuvre de tels marqueurs et application des cellules contenant un tel marqueur a la fabrication de proteines determinees apres leur transformation par un adn correspondant
EP0062574A3 (de) * 1981-03-31 1982-12-29 The Regents Of The University Of California Synthese von Virusproteinen
JPS58201988A (ja) * 1982-05-04 1983-11-25 ベ−リンガ−・マンハイム・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング 永久培養可能な動物及びヒトの細胞系を得る方法
DE3245665A1 (de) * 1982-05-04 1983-11-10 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur herstellung permanenter tierischer und humaner zellinien und deren verwendung
US4608339A (en) * 1983-10-25 1986-08-26 Yoakum George H Protoplast fusion method for high-frequency DNA transfection in human cells
FR2555607B2 (fr) * 1983-11-30 1986-10-03 Pasteur Institut Culture de cellules eucaryotes productrices d'une proteine vaccinante, notamment d'antigene hbs
FR2565995B1 (fr) * 1984-03-07 1987-10-23 Centre Nat Rech Scient Cellules hybrides productrices d'un polypeptide determine et obtenu a partir de cellules primaires naturellement capables d'exprimer ce polypeptide ou un polypeptide equivalent, procede pour l'obtention de ces cellules hybrides et application de celles-ci a la production dudit polypeptide

Also Published As

Publication number Publication date
DK204586D0 (da) 1986-05-02
JPS6229971A (ja) 1987-02-07
PT82505B (pt) 1989-12-29
DE3669529D1 (de) 1990-04-19
DK204586A (da) 1986-11-03
PT82505A (fr) 1986-06-01
WO1993013203A1 (fr) 1993-07-08
EP0200653A1 (de) 1986-11-05
ES8703519A1 (es) 1987-03-01
CA1277934C (fr) 1990-12-18
US5112748A (en) 1992-05-12
FR2581393A2 (fr) 1986-11-07
EP0200653B1 (de) 1990-03-14
FR2581393B2 (fr) 1989-07-21
ES555123A0 (es) 1987-03-01
GR861142B (en) 1986-08-11

Similar Documents

Publication Publication Date Title
DK15182A (da) Fremgangsmaade til fremstilling af recombinant-dna
DE69031791D1 (de) Verfahren zur HCV-Züchtung in Zell-Linien aus B- oder T-Lymphozyten
BE880670A (fr) Procede de production d'un adn comprenant le genome du virus de l'hepatite b et vecteur le comportant
DK577783A (da) Vektor for udtrykkelse af et dna-segment i gaer
ES2167304T3 (es) Peptido que contiene el antigeno de superficie de la hepatitis b.
DE3177298D1 (de) Verbesserte vektoren, verfahren zur herstellung solcher vektoren und zur expression von klonierten genen.
ATE215563T1 (de) Verfahren zur herstellung von menschlichen monoklonalen antikörpern und deren verwendung
AT365096B (de) Verfahren zur herstellung von sphaeroidischen, bei raumtemperatur festen produkten
MX26714A (es) Procedimiento para la preparacion de albumina de SUERO HUMANO VECTOR Y PLASMIDO USADOS ASI COMO LEVADURA METILOTROFICA TRANSFORMADA OBTENIDA
ATE152124T1 (de) Wachstumsfaktor aus parenchymalen lebenszellen, dafür kodierendes gen, verfahren zur herstellung dieses faktors und transformanten
DE3176404D1 (en) Vaccine against viral hepatitis b, method and transformed eucaryotic cells for the preparation of this vaccine
ATE454039T1 (de) Verfharen zur herstellung von herpes-simplex- virus-amplikons, die resultierenden amplikons und ihre verwendung
PT73021B (en) Process for producing dna sequences of recombinant dna molecules and polipeptides with specificyty on foot mouth disease as viral antigens
ATE2442T1 (de) Verfahren zur herstellung von interferon und dabei verwendete kulturmediumzusammensetzung.
ATE16454T1 (de) Influenzavirus-vaccine, verfahren zu ihrer herstellung und verfahren zur vermehrung von influenzaviren.
DE3585578D1 (de) Hepatitisoberflaechenantigenpartikelvakzin.
DE68907735D1 (de) Genfragmente, die die variable region eines anti-hiv-antikoerpers codieren, von diesen exprimierte chimaere anti-hiv-antikoerper und verfahren zu deren herstellung.
DE3669529D1 (de) Hybridzellen, die ein hepatitis-b-virus-antigen produzieren, aus hepatocyten und errichteten affenzellen, verfahren zur herstellung dieser hybridzellen und verwendung derselben zur herstellung der obenerwaehnten antigens.
EP0105141A3 (de) Rekombinante DNS Moleküle, Verfahren zu deren Herstellung, deren Verwendung zur Herstellung von Hepatitis B Oberflächen-Antigen (HBsAg) und pharmazeutische Zusammensetzungen die das HBsAg enthalten
ATE31733T1 (de) Verfahren zur herstellung von hybridisierungssonden.
DK326289A (da) Fremgangsmaade til fremstilling af et protein ud fra gaersvampe under anvendelse af et inducerbart system, samt vektorer og transformerede stammer til brug ved fremgangsmaaden
DE3779032D1 (de) Dns-sequenz, vektoren, rekombinante viren und verfahren zur verwendung rekombinanter vaccinia-viren, die sich in cho-zellen vermehren koennen.
ATE128730T1 (de) Prototypische felv-isolate für die verwendung als krankheitsmuster oder impfstoffe.
DE3587205D1 (de) Verfahren zur herstellung eines proteins und dafuer zu verwendender vektor, rekombinante dns und transformierte zelle.
DE69322227D1 (de) Verfahren zur herstellung von lebenden zellkulturen, die durch einen multiple sklerose assoziierten virus infiziert sind

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee